HOOKIPA Pharma Inc. (NASDAQ:HOOK)

HOOKIPA Pharma Inc. HOOK

Healthcare - Biotechnology - NASDAQ - US

Watchlist

$ 3.0

-4.46 %

$ 36.2 M

Market Cap

-0.73

P/E

1. INTRINSIC VALUE

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc.[ Read More ]

The intrinsic value of one HOOK stock under the base case scenario is HIDDEN Compared to the current market price of 3 USD, HOOKIPA Pharma Inc. is HIDDEN

HOOK Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart HOOK

FINANCIALS

Annual
Quarterly

20.1 M REVENUE

Growth Rates

1Year 41.27%

3Years 0.92%

5Years 21.41%

7Years 0.00%

10Years 0.00%

-97.7 M OPERATING INCOME

Growth Rates

1Year -33.54%

3Years -22.39%

5Years -35.77%

7Years 0.00%

10Years 0.00%

-81.6 M NET INCOME

Growth Rates

1Year -25.67%

3Years -22.77%

5Years -38.11%

7Years 0.00%

10Years 0.00%

-57.5 M OPERATING CASH FLOW

Growth Rates

1Year -187.66%

3Years -13.50%

5Years -30.85%

7Years 0.00%

10Years 0.00%

-4.16 M INVESTING CASH FLOW

Growth Rates

1Year 17.10%

3Years -20.60%

5Years -14.11%

7Years 0.00%

10Years 0.00%

65.7 M FINANCING CASH FLOW

Growth Rates

1Year -9.13%

3Years -3.65%

5Years 57.05%

7Years 0.00%

10Years 0.00%

0 REVENUE

Growth Rates

1Year 41.27%

3Years 0.92%

5Years 21.41%

7Years 0.00%

10Years 0.00%

-18.6 M OPERATING INCOME

Growth Rates

1Year -33.54%

3Years -22.39%

5Years -35.77%

7Years 0.00%

10Years 0.00%

-13.8 M NET INCOME

Growth Rates

1Year -25.67%

3Years -22.77%

5Years -38.11%

7Years 0.00%

10Years 0.00%

-17.5 M OPERATING CASH FLOW

Growth Rates

1Year -187.66%

3Years -13.50%

5Years -30.85%

7Years 0.00%

10Years 0.00%

-31 K INVESTING CASH FLOW

Growth Rates

1Year 17.10%

3Years -20.60%

5Years -14.11%

7Years 0.00%

10Years 0.00%

0 FINANCING CASH FLOW

Growth Rates

1Year -9.13%

3Years -3.65%

5Years 57.05%

7Years 0.00%

10Years 0.00%

Balance Sheet Decomposition HOOKIPA Pharma Inc.

161 M ASSETS
71.5 M LIABILITIES

Current Assets	147 M
Cash & Short-Term Investments	117 M
Receivables	19.3 M
Other Current Assets	10.7 M
Non-Current Assets	14.2 M
Long-Term Investments	0
PP&E	13.2 M
Other Non-Current Assets	1.01 M

Current Liabilities	42 M
Accounts Payable	12.5 M
Short-Term Debt	4.4 M
Other Current Liabilities	25.1 M
Non-Current Liabilities	29.5 M
Long-Term Debt	3.8 M
Other Non-Current Liabilities	25.7 M

EFFICIENCY

Earnings Waterfall HOOKIPA Pharma Inc.

Revenue	20.1 M
Cost Of Revenue	3.55 M
Gross Profit	16.6 M
Operating Expenses	32.7 M
Operating Income	-97.7 M
Other Expenses	-16.1 M
Net Income	-81.6 M

RATIOS

82.35% GROSS MARGIN

Averages

1Year 82.35%

3Years 77.31%

5Years -45.44%

7Years -59.30%

10Years 0.00%

-485.34% OPERATING MARGIN

Averages

1Year -485.34%

3Years -480.49%

5Years -428.27%

7Years -345.56%

10Years 0.00%

-405.29% NET MARGIN

Averages

1Year -405.29%

3Years -423.67%

5Years -371.30%

7Years -295.62%

10Years 0.00%

-90.79% ROE

Averages

1Year -90.79%

3Years -79.52%

5Years -60.66%

7Years -44.29%

10Years 0.00%

-50.56% ROA

Averages

1Year -50.56%

3Years -49.56%

5Years -40.42%

7Years -34.73%

10Years 0.00%

-105.96% ROIC

Averages

1Year -105.96%

3Years -87.03%

5Years -63.92%

7Years -46.67%

10Years 0.00%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis HOOKIPA Pharma Inc.

Net Income	-81.6 M
Depreciation & Amortization	3.55 M
Capital Expenditures	-4.16 M
Stock-Based Compensation	2.34 M
Change in Working Capital	5.33 M
Others	8.21 M
Free Cash Flow	-61.7 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets HOOKIPA Pharma Inc.

HOOK has no price targets from Wall Street.

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

0 USD DIVIDEND PER SHARE

5. COMPETITION

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally.

-0.0218 USD

MREO

Overvalued 100.62%

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity.

1.11 USD

TERN

Overvalued 81.96%

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.

1.06 USD

PDSB

Overvalued 47.42%

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases.

-0.232 USD

INZY

Overvalued 107.41%

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

2.89 USD

DAWN

Overvalued 78.30%

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant.

0.172 USD

ELDN

Overvalued 95.71%

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.

0.23 USD

XFOR

Overvalued 42.95%

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.

0.79 USD

ABOS

Overvalued 67.09%

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

-14.6 USD

AMLX

Overvalued 407.28%

6. Ownership

Insider Ownership HOOKIPA Pharma Inc.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
1 year ago Aug 21, 2023	Bought 5.08 K USD	Kandera Reinhard Chief Financial Officer	+ 7000	0.725 USD
1 year ago Aug 16, 2023	Bought 5.71 K USD	Kandera Reinhard Chief Financial Officer	+ 8000	0.714 USD
1 year ago Jul 11, 2023	Bought 4.14 K USD	Aldag Jorn Chief Executive Officer	+ 5000	0.8284 USD
1 year ago Jul 07, 2023	Bought 4.05 K USD	Aldag Jorn Chief Executive Officer	+ 5000	0.81 USD
1 year ago Jul 05, 2023	Bought 4.45 K USD	Aldag Jorn Chief Executive Officer	+ 5000	0.89 USD
1 year ago Jul 03, 2023	Bought 4.46 K USD	Aldag Jorn Chief Executive Officer	+ 5000	0.8911 USD
1 year ago Jun 30, 2023	Bought 10.6 K USD	Kandera Reinhard Chief Financial Officer	+ 12000	0.88 USD
2 years ago Dec 21, 2021	Sell 5.49 K USD	Matushansky Igor Chief Medical Officer	- 2205	2.49 USD
2 years ago Dec 21, 2021	Sell 18.5 K USD	Matushansky Igor Chief Medical Officer	- 7440	2.49 USD
2 years ago Dec 21, 2021	Sell 13.2 K USD	Matushansky Igor Chief Medical Officer	- 5304	2.49 USD
3 years ago Apr 21, 2021	Sell 3.81 M USD	SOFINNOVA CAPITAL VI FCPR 10 percent owner	- 328620	11.6012 USD
3 years ago Mar 29, 2021	Sell 504 K USD	SOFINNOVA CAPITAL VI FCPR 10 percent owner	- 36829	13.6732 USD
3 years ago Mar 26, 2021	Sell 482 K USD	SOFINNOVA CAPITAL VI FCPR 10 percent owner	- 35171	13.6943 USD
3 years ago Mar 25, 2021	Sell 375 K USD	SOFINNOVA CAPITAL VI FCPR 10 percent owner	- 28546	13.1216 USD
3 years ago Mar 24, 2021	Sell 722 K USD	SOFINNOVA CAPITAL VI FCPR 10 percent owner	- 52690	13.6955 USD
3 years ago Mar 23, 2021	Sell 556 K USD	SOFINNOVA CAPITAL VI FCPR 10 percent owner	- 40000	13.9119 USD
3 years ago Mar 22, 2021	Sell 589 K USD	SOFINNOVA CAPITAL VI FCPR 10 percent owner	- 40534	14.5375 USD
3 years ago Mar 19, 2021	Sell 2.43 M USD	SOFINNOVA CAPITAL VI FCPR 10 percent owner	- 166230	14.6047 USD
3 years ago Dec 17, 2020	Sell 194 K USD	Matushansky Igor Chief Medical Officer	- 16478	11.76 USD
3 years ago Dec 17, 2020	Sell 135 K USD	Matushansky Igor Chief Medical Officer	- 11501	11.7 USD
3 years ago Dec 16, 2020	Sell 4.45 K USD	Matushansky Igor Chief Medical Officer	- 380	11.7 USD
4 years ago Oct 02, 2020	Sell 3 K USD	SOFINNOVA CAPITAL VI FCPR 10 percent owner	- 300	10 USD
4 years ago Sep 15, 2020	Sell 403 K USD	SOFINNOVA CAPITAL VI FCPR 10 percent owner	- 32336	12.4494 USD
4 years ago Sep 15, 2020	Sell 122 K USD	SOFINNOVA CAPITAL VI FCPR 10 percent owner	- 9261	13.1641 USD
4 years ago Jun 29, 2020	Sell 38.6 K USD	SOFINNOVA CAPITAL VI FCPR 10 percent owner	- 3280	11.7767 USD
4 years ago Jun 29, 2020	Sell 38.6 K USD	SOFINNOVA CAPITAL VI FCPR 10 percent owner	- 3280	11.7767 USD
4 years ago Jul 20, 2020	Sell 149 K USD	SOFINNOVA CAPITAL VI FCPR 10 percent owner	- 12483	11.9444 USD
4 years ago Jun 29, 2020	Sell 38.6 K USD	SOFINNOVA CAPITAL VI FCPR 10 percent owner	- 3280	11.7767 USD
4 years ago Jan 29, 2020	Sell 70 K USD	Matushansky Igor Chief Medical Officer	- 5500	12.7259 USD
4 years ago Jan 23, 2020	Sell 49.6 K USD	Lilja Anders Sr. VP, Technical Development	- 4075	12.1721 USD
4 years ago Jan 23, 2020	Sell 96.9 K USD	Lilja Anders Sr. VP, Technical Development	- 7568	12.8081 USD
4 years ago Jan 21, 2020	Sell 81.6 K USD	Orlinger Klaus Sr. VP, Research	- 6789	12.0182 USD
4 years ago Jan 16, 2020	Sell 19.8 K USD	Orlinger Klaus Sr. VP, Research	- 1711	11.5612 USD
4 years ago Jan 14, 2020	Sell 96.1 K USD	Orlinger Klaus Sr. VP, Research	- 8500	11.3003 USD
4 years ago Dec 19, 2019	Sell 103 K USD	Matushansky Igor Chief Medical Officer	- 10404	9.93 USD
4 years ago Dec 17, 2019	Sell 90.4 K USD	Matushansky Igor Chief Medical Officer	- 11484	7.87 USD
5 years ago Apr 23, 2019	Bought 750 K USD	Forbion Capital Fund II Cooperatief U.A. 10 percent owner	+ 53571	14 USD
5 years ago Apr 23, 2019	Bought 5 M USD	SOFINNOVA CAPITAL VI FCPR 10 percent owner	+ 357142	14 USD
5 years ago Apr 23, 2019	Bought 11.5 M USD	BAKER BROS. ADVISORS LP	+ 820729	14 USD
5 years ago Apr 23, 2019	Bought 1.01 M USD	BAKER BROS. ADVISORS LP	+ 72128	14 USD

7. News

HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety globenewswire.com - 5 days ago

HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024 Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024 globenewswire.com - 2 weeks ago

HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer Study done in collaboration with Memorial Sloan Kettering and led by Dr. Winston Wong, Head and Neck Oncologist and Dr. Alan Ho, Chief of the Head and Neck Oncology Service globenewswire.com - 2 weeks ago

HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024 Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024 globenewswire.com - 1 month ago

Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet The mean of analysts' price targets for HOOKIPA Pharma (HOOK) points to a 622.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 2 months ago

HOOKIPA Pharma Announces Board of Directors Changes NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (“HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O'Neill as Non-Executive Chair of the Company's Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab A/S. The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his other professional responsibilities. globenewswire.com - 2 months ago

HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference NEW YORK and VIENNA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of the management team will participate in the H.C. Wainwright 26th Annual Global Investment Conference, taking place from September 9th-11th, 2024 in New York. globenewswire.com - 2 months ago

HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 “AVALON-1” study with eseba-vec in Q4 2024 globenewswire.com - 3 months ago

Wall Street Analysts Believe HOOKIPA Pharma (HOOK) Could Rally 634.38%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 634.4% in HOOKIPA Pharma (HOOK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 3 months ago

Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know HOOKIPA Pharma (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 months ago

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200 NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (”HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice President and Chief Financial Officer, effective July 22, 2024. They will both retain their positions on the Board of Directors (“Board”). globenewswire.com - 3 months ago

HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split NEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that a 1-for-10 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m. Eastern Time on July 9, 2024. globenewswire.com - 4 months ago

8. Profile Summary

HOOKIPA Pharma Inc. HOOK

COUNTRY US

INDUSTRY Biotechnology

MARKET CAP $ 36.2 M

Dividend Yield 0.00%

Description HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

Contact 350 Fifth Avenue, New York, NY, 10118 https://www.hookipapharma.com

IPO Date April 18, 2019

Employees 151

Officers Mr. Lukas Flatz Co-Founder Ms. Mary Theresa Coelho M.B.A. Executive Vice President, Chief Financial Officer & Director Dr. Mark Winderlich Ph.D. Chief Research & Development Officer Mr. Michael Szumera Executive Director of Communications Mr. Andreas Bergthaler Co-Founder Dr. Malte Peters M.D. Chief Executive Officer & Director Prof. Rolf M. Zinkernagel M.D., Ph.D. Co-Founder Mr. Matthew L. S. Beck Executive Director of Investor Relations Dr. Klaus Orlinger Ph.D. Chief Scientific Officer Dr. Roman Necina Ph.D. Chief Operations Officer

Price Chart HOOK

HOOKIPA Pharma Inc. HOOK

Premium Plan

Unlimited Plan